Correlation between HBsAg and HBV genome concentrations acording to genotype

1
(No Transcript)
2
HBsAg candidate blood donors
HBV genotypes Number Origin(s)
A1 43 S. Africa
A2 72 Poland
B 126 Hong Kong Malaysia Taiwan Thailand
C 90 Hong Kong Malaysia Taiwan Thailand
D 465 Egypt Iran Poland S. Africa Turkey Tunisia

E 184 Guinea
HBsAg quantification Architect HBsAg, Abbott
Lab. (0.05 IU/ml or 0.28 ng/ml) HBV DNA
quantification in-house real-time QPCR assay
(lt20 IU/ml)
3
(No Transcript)
4
Relationship between HBsAg and HBV DNA levels
A1
A2
B
5
6
5
5
4
4
4
HBsAg (log IU/ml)
HBsAg (log IU/ml)
3
HBsAg (log IU/ml)
3
3
2
2
2
1
R20.08
1
R20.02
1
R20.39
2
4
6
8
10
2
4
6
8
10
2
4
6
8
10
12
HBV DNA (log IU/ml)
HBV DNA (log IU/ml)
HBV DNA (log IU/ml)
n43
n72
n126
C
D
E
6
6
6
5
5
5
4
4
4
HBsAg (log IU/ml)
HBsAg (log IU/ml)
HBsAg (log IU/ml)
3
3
3
2
2
2
R20.31
1
R20.17
1
1
R20.22
2
4
6
8
10
2
4
6
8
10
2
4
6
8
10
HBV DNA (log IU/ml)
HBV DNA (log IU/ml)
HBV DNA (log IU/ml)
n90
n465
n184
5
HBsAg / HBV DNA ratio
n43
n72
Frequency ()
n126
n90
D
30
n465
n184
20
10
0
gt1
lt1
1
Ratio
6
(No Transcript)
7
HBsAg / HBV DNA ratio according to ethnic groups
8
Conclusions

• HBsAg range is between 102 and 106 IU/ml for
  genotypes A, C and E. Significantly lower values
  are seen in genotypes B and D.
• A1, B and D have lower median DNA than
  genotypes A2, C and E
• No correlation between plasma levels of HBsAg
  and viral load irrespective of genotype
• Very low HBsAg (3.7) or DNA (6.2) levels are
  observed in genotype D
• Within genotype B infection HBsAg and DNA
  levels are significantly higher in Chinese than
  Malays

9
Acknowledgements
B Meldal P Garmiri D Belkhiri Dept
Haematology University of Cambridge, UK
K Lin, HKRCBTS, Hong Kong T Sakul, NRCBTS,
Bangkok, Thailand M Vermeulen, SANBTS, Durban,
SA E Brojer, NIHTM, Warsaw, Poland A Loua, CNTS,
Conakry, Guinea H Bon, NBTS, Kuala Lumpur,
Malaysia K Boukef, NBTS, Tunis, Tunisia O Arslan,
Ankara, Turkey H Zadeh, IBTO, Teheran, Iran M El
Ekiaby, Cairo, Egypt
B Foglieni Dept of Transfusion Medicine and
Hematology, Lecco, Italy
Supported by ISBT Foundation NHSBT,
England Novartis